Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended September 2026, Astrazeneca (AZN) reported revenue of $16.21 billion, up 6.7% over the same period last year. EPS came in at $2.79, compared to $2.38 in the year-ago quarter.

The reported revenue represents a surprise of +0.71% over the Zacks Consensus Estimate of $16.09 billion. With the consensus EPS estimate being $2.60, the EPS surprise was +7.31%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Astrazeneca performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• BioPharmaceuticals- R&I- Symbicort- U.S.: $227 million versus $251.63 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -25.6% change.

• BioPharmaceuticals- R&I- Fasenra- U.S.: $355 million compared to the $354.75 million average estimate based on two analysts. The reported number represents a change of +7.6% year over year.

• Rare Disease- Koselugo- U.S.: $55 million versus the two-analyst average estimate of $51.77 million.

• BioPharmaceuticals- CVRM- Lokelma- U.S.: $75 million versus $91.02 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -8.5% change.

• BioPharmaceuticals- R&I- Symbicort- World: $666 million versus $681.41 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -10.2% change.

• Other Medicines- World: $227 million versus the two-analyst average estimate of $223.46 million.

• BioPharmaceuticals- CVRM- Crestor- World: $332 million compared to the $328.13 million average estimate based on two analysts. The reported number represents a change of +8.9% year over year.

• BioPharmaceuticals- CVRM- Seloken- World: $181 million compared to the $161.83 million average estimate based on two analysts. The reported number represents a change of +13.1% year over year.

• Oncology- Zoladex- World: $325 million compared to the $292.55 million average estimate based on two analysts.

• Oncology- Tagrisso- World: $2.09 billion versus $1.98 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +12% change.

• BioPharmaceuticals- R&I- Fasenra- World: $602 million versus $590.51 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +13.6% change.

• BioPharmaceuticals- CVRM- Brilinta- World: $75 million versus $86.17 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -48.6% change.